Humana (HUM) Q1 2025 Earnings Call April 30, 2025 08:00 AM ET Company Participants Lisa Stoner - Vice President-Investor RelationsJames Rechtin - President & CEOCeleste Mellet - CFOBen Hendrix - Vice PresidentGeorge Renaudin - President of Medicare & Medicaid and DirectorAndrew Mok - DirectorA.J. Rice - Managing DirectorJoshua Raskin - Partner - Managed Care & ProvidersLance Wilkes - Managing DirectorLisa Gill - Managing DirectorDavid Windley - Managing Director Conference Call Participants Sarah James - An ...

Financial Data and Key Metrics Changes - The company revised its adjusted earnings per share outlook for 2025 to $26 to $26.50, reflecting performance challenges primarily in its Medicare businesses [7][29] - The consolidated revenue outlook remains at $450 billion to $455 billion, with expectations for UnitedHealthcare and Optum Rx revenues to exceed initial views, offsetting a reduced outlook for Optum Health [30][31] - The full year medical care ratio is now expected to be 87.5% plus or minus 50 basis points, indicating higher utilization across senior populations [31] Business Line Data and Key Metrics Changes - UnitedHealthcare's Medicare Advantage business is projected to serve an additional 800,000 people in 2025, while Optum Health aims to add 650,000 net new patients to value-based care arrangements [16][43] - Optum Rx revenues grew by 14%, exceeding $35 billion for the quarter, with script growth of 3% driven by customer retention and new customer wins [44] Market Data and Key Metrics Changes - The company noted a significant increase in care activity in its Medicare Advantage business, with first quarter indications suggesting care activity increased at twice the rate anticipated [10][29] - The company experienced a sharp increase in elective care activity, particularly in the group Medicare Advantage segment, attributed to higher member premiums driven by Medicare funding cuts [36][66] Company Strategy and Development Direction - The company is focusing on improving engagement with complex patients and enhancing clinical workflows to transition effectively to the new CMS risk model [15][39] - The company continues to innovate in its service offerings, such as the HouseCalls program, which provides in-home clinical visits to seniors [21][22] - The company emphasizes the importance of transparency and affordability in healthcare, aiming to reduce costs for consumers while maintaining high-quality care [28][132] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment with current performance but remains committed to improving results throughout 2025 and into 2026, targeting long-term earnings per share growth of 13% to 16% [46][47] - The management acknowledged the challenges posed by recent Medicare funding cuts and the need to better anticipate and address second-order effects in the market [90][96] Other Important Information - The company is actively engaging with state customers to address Medicaid funding issues and is optimistic about recent rate adjustments aligning more closely with member acuity [41][130] - The company is concerned about legislative changes affecting pharmacy benefit managers (PBMs) and their potential impact on patient access to medications [126][127] Q&A Session Summary Question: Medicare Advantage cost trend expectations - Management indicated that care levels were anticipated to be consistent with 2024 but have seen a significant increase in the first quarter, particularly in physician and outpatient services [49][55] Question: Connection between primary care visits and Optum Health performance - Management clarified that while primary care visits have increased, the challenges in Optum Health are due to the profile of new value-based patients and the impact of the V28 phase [58][68] Question: Impact of elevated care on group Medicare Advantage - Management confirmed that the elevated care activity is primarily observed in community and group Medicare Advantage, influenced by premium increases [98][102] Question: Long-term growth rate recovery - Management expressed confidence in returning to long-term growth rates, supported by improved 2026 rates and ongoing engagement with state partners [106][110] Question: Medicare Advantage margins and timeline for recovery - Management stated that margins for Medicare Advantage are still within targeted ranges for 2025, with expectations to return to historical planning targets in 2026 [114][118] Question: Policy implications of PBM reform and Medicaid funding - Management highlighted their leadership in transparency and affordability in the PBM space and emphasized the importance of maintaining access to medications for patients [122][130]

P3 Health Partners (PIII) Q4 2024 Earnings Call March 27, 2025 04:30 PM ET Company Participants Ryan Halsted - Managing DirectorAric Coffman - CEOLeif Pedersen - Chief Financial OfficerAmir Bacchus - Co-Founder and Chief Medical OfficerAaron Wukmir - Healthcare Equity Research AssociateJoshua Raskin - Partner - Managed Care & ProvidersDavid Larsen - Managing Director Conference Call Participants Ryan Langston - Director & Senior Analyst - Healthcare ResearchJack Sampson - Analyst Operator Good day and welco ...

BrightSpring Health Services (BTSG) Q4 2024 Earnings Call March 06, 2025 08:30 AM ET Company Participants David Deuchler - Managing DirectorJon Rousseau - Chairman, President & CEOJennifer Phipps - EVP & CFOA.J. Rice - Managing DirectorWhit Mayo - Senior Managing DirectorMatthew Gillmor - Director & Senior Research Aanalyst Conference Call Participants Brian Tanquilut - Equity Research Analyst - Healthcare ServicesDavid Larsen - Analyst, Managing DirectorJoanna Gajuk - Equity Research AnalystErin Wright - S ...

Health Catalyst (HCAT) Q4 2024 Earnings Call February 26, 2025 05:00 PM ET Company Participants Jack Knight - VP - Investor RelationsDan Burton - CEODan Lesueur - COOJason Alger - Chief Financial OfficerJared Haase - Equity Research AssociateAnne Samuel - Executive DirectorSameer Patel - VP - Equity ResearchScott Schoenhaus - Managing DirectorGabrielle Ingoglia - Equity Research Associate Conference Call Participants Jessica Tassan - Senior Equity Research AnalystJohn Pinney - AnalystDaniel Grosslight - Sen ...